Literature DB >> 12648582

TAP1, TAP2, and HLA-DR2 alleles are predictors of cervical cancer risk.

Bobbie S Gostout1, Gregory A Poland, Eric S Calhoun, Youvraj R Sohni, Robert L Giuntoli, Renee M McGovern, Jeff A Sloan, Stephen S Cha, David H Persing.   

Abstract

OBJECTIVE: The likelihood of developing cervical cancer has been shown to be increased in persons with certain HLA alleles. We evaluated immune response genes in the HLA region of chromosome 6 to see if individual or interactive associations with cervical cancer risk could be identified.
METHODS: Tissue was obtained from 127 women undergoing surgical treatment for cervical cancer. Blood samples were obtained from 175 control subjects. A combination of polymerase chain reaction (PCR), sequence-specific PCR, and DNA sequencing was used to evaluate polymorphic alleles, including HLA class I B7, TNF alpha, HLA class II DR2, TAP1, and TAP2 genes. Fisher's exact test and logistic regression modeling were used for statistical analysis.
RESULTS: A significantly greater proportion of the patients with cervical cancer were found to have the HLA class II DR2 1501 allele (P = 0.023) and the TAP2 A/B heterozygous pattern of alleles (P = 0.0006) than were women without cervical cancer. A proportion of patients with cervical cancer significantly smaller than that of the control women had a polymorphism at the -238 position of the TNF promoter and the TAP1 C/C homozygous pattern of alleles. With logistic modeling, the markers that showed consistent association with the occurrence of cervical cancer were TAP2 A/B, HLA-DR2 1501, and TAP1 C/C.
CONCLUSIONS: We demonstrated a significant association between immune response genes and the risk of cervical cancer. Our data create a compelling argument for a gene or a cluster of genes in the HLA region of chromosome 6 that regulates host immune responses to human papillomavirus infection in a manner that results in inherited susceptibility or resistance to the transforming properties of oncogenic papillomaviruses.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12648582     DOI: 10.1016/s0090-8258(02)00074-4

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  21 in total

1.  TNF-α and IL-10 promoter polymorphisms, HPV infection, and cervical cancer risk.

Authors:  Gisela Barbisan; Luis Orlando Pérez; Anahí Contreras; Carlos Daniel Golijow
Journal:  Tumour Biol       Date:  2012-05-17

2.  Association between tumor necrosis factor alpha rs1800629 polymorphism and risk of cervical cancer.

Authors:  Lanling Wang; Kunpeng Ma; Zhiyong Wang; Yingying Mou; Li Ma; Yong Guo
Journal:  Int J Clin Exp Med       Date:  2015-02-15

3.  Tumor Necrosis Factor Alpha (-238 / -308) and TNFRII-VNTR (-322) Polymorphisms as Genetic Biomarkers of Susceptibility to Develop Cervical Cancer Among Tunisians.

Authors:  Sabrina Zidi; Mouna Stayoussef; Ferjeni Zouidi; Samir Benali; Ezzedine Gazouani; Amel Mezlini; Besma Yacoubi-Loueslati
Journal:  Pathol Oncol Res       Date:  2014-08-12       Impact factor: 3.201

4.  A systemic assessment of the association between tumor necrosis factor alpha 308 G/A polymorphism and risk of cervical cancer.

Authors:  Hua-Lian Zhang; Yi-Jie Zhang
Journal:  Tumour Biol       Date:  2013-03-15

5.  Genetic variants in TAP are associated with high-grade cervical neoplasia.

Authors:  Mark H Einstein; Suzanne Leanza; Lydia G Chiu; Nicolas F Schlecht; Gary L Goldberg; Bettie M Steinberg; Robert D Burk
Journal:  Clin Cancer Res       Date:  2009-02-01       Impact factor: 12.531

Review 6.  Personalized vaccines: the emerging field of vaccinomics.

Authors:  Gregory A Poland; Inna G Ovsyannikova; Robert M Jacobson
Journal:  Expert Opin Biol Ther       Date:  2008-11       Impact factor: 4.388

7.  Association between TNF-α polymorphisms and cervical cancer risk: a meta-analysis.

Authors:  Li Liu; Xi Yang; Xiaojun Chen; Tinjing Kan; Yan Shen; Zengyan Chen; Zhibin Hu
Journal:  Mol Biol Rep       Date:  2011-06-14       Impact factor: 2.316

8.  TNF-alpha rs1800629 polymorphism is not associated with HPV infection or cervical cancer in the Chinese population.

Authors:  Ning Wang; Duo Yin; Shulan Zhang; Heng Wei; Shizhuo Wang; Yang Zhang; Yanming Lu; Shuyan Dai; Wei Li; Qiao Zhang; Yao Zhang
Journal:  PLoS One       Date:  2012-09-13       Impact factor: 3.240

9.  Tumor necrosis factor alpha rs1800629 polymorphism and risk of cervical lesions: a meta-analysis.

Authors:  Min Li; Ying Han; Ting-Ting Wu; Yichen Feng; Hong-Bo Wang
Journal:  PLoS One       Date:  2013-08-27       Impact factor: 3.240

10.  The TNF-alpha-238 polymorphism and cancer risk: a meta-analysis.

Authors:  Ping Zhou; Guo-Qiang Lv; Jian-Zhong Wang; Cheng-Wan Li; Liang-Feng Du; Chun Zhang; Jian-Ping Li
Journal:  PLoS One       Date:  2011-07-19       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.